Click on headlines below to download research
On track to reach high-end FY24 sales guidance
JDC Group | 18/11/2024
After two quarters of >20% y-o-y revenue growth, JDC Group (JDC) has benefited from strong tailwinds in Q324 as well. Revenue growth of 36% in the quarter…
Focus remains on profitability and cash
CLIQ Digital | 13/11/2024
CLIQ’s Q3 results show the continuing revenue impact of the shift in credit card providers’ policies on transaction cancellations. Revenues…
Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies
Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies | 29/10/2024
Medigene is a publicly listed, Germany-based, immuno-oncology platform company focused on the development of T cell receptor (TCR)-guided therapies with…
A key milestone with significance for the sector
BB Biotech | 21/10/2024
BB Biotech (BION) invests in innovative, rapidly expanding biotech companies. BION’s portfolio company Wave Life Sciences (Wave) recently announced…
Executive interview
BB Biotech – executive interview (14 October 2024) | 14/10/2024
In this interview, we speak to Dr Christian Koch, deputy head of investment management at BB Biotech (BION), the Switzerland-based investment company listed…
Executive interview
HBM Healthcare Investments – executive interview (9 October 2024) | 09/10/2024
HBM Healthcare Investments (SIX: HBMN) is a Swiss investment company focused on the global healthcare sector, with a particular focus on private equity…
Executive interview
Medigene – executive interview (30 September 2024) | 30/09/2024
Medigene (FSE: MDG1) is a publicly listed, Germany-based, immuno-oncology platform company focused on the development of T cell receptor (TCR)-guided therapies…
Increasing profitability and margins
Nabaltec | 02/09/2024
Nabaltec recorded 2.2% y-o-y growth in its H124 revenue (€108.4m). The company’s strong performance in its functional filler segment was the…
Gaining a firm foothold in commercial insurers
JDC Group | 19/08/2024
JDC Group’s (JDC’s) H124 results were strong, with organic revenue growth close to 20% and an EBITDA margin of 6.5% (H123: 6%). Management…
Lower rates and news flow to support recovery
BB Biotech | 14/08/2024
BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment…
Doubling down on investment opportunities
Deutsche Beteiligungs | 14/08/2024
Deutsche Beteiligungs (DBAG) reported a c 4% NAV total return in 9M24, supported primarily by higher valuation multiples on the back of more benign public…
Sales decline decelerating in Q224
CLIQ Digital | 13/08/2024
CLIQ Digital’s H124 results were as expected following the July trading update, at which point the company lowered its guidance. The change in the…
FY24 outlook weakened
CLIQ Digital | 31/07/2024
CLIQ Digital has lowered its financial outlook for FY24 due to the transition to new sales channels in H124. This was coupled with elevated churn following…
High-tech white powders
Nabaltec | 31/07/2024
Nabaltec is a leading global producer of functional fillers and specialty alumina, serving a wide range of growing end-uses including halogen-free flame…
Executive interview
JDC Group – executive interview (9 July 2024) | 09/07/2024
JDC Group is Germany’s leading insurtech company, offering a platform on which clients can manage insurance portfolios from hundreds of German insurance…
Market environment turning slightly more positive
Heliad | 04/07/2024
Heliad reported a net asset value (NAV) per share of €18.20 at end-March 2024, roughly unchanged compared to end-September 2023 (€18.17), as…
Convertible bond issue
Deutsche Beteiligungs | 02/07/2024
Deutsche Beteiligungs (DBAG) completed an issue of €100m senior unsecured convertible bonds on 28 June, with proceeds to be used for co-investments…
Positive trial news lifts two portfolio holdings
BB Biotech | 26/06/2024
In our last BB Biotech (BION) review note, published in May 2024, we noted that the biotech sector was eagerly awaiting some key milestones, the most important…
2024: The year of M&A?
Edison Growth Conference panel – 2024: The year of M&A? | 19/06/2024
The second panel at the inaugural Edison Growth Conference 2024 was titled ‘2024 – the year of M&A?’ After a two-year bear market, where…
Successful exits assist H124 performance
Deutsche Beteiligungs | 28/05/2024
Deutsche Beteiligungs (DBAG) reported an NAV total return of 3% in H124 (to March 2024) following the first-time recognition of 2024 portfolio company…
London calling
Borussia Dortmund | 21/05/2024
Borussia Dortmund’s Q324 results demonstrated some phasing but it has made good progress year-to-date. The focus of attention now is the team’s…
A recovering sector with a healthy prognosis
BB Biotech | 20/05/2024
BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment…
Increased churn weakens FY24 outlook
CLIQ Digital | 14/05/2024
CLIQ Digital delivered a disappointing start to FY24 in Q124, as its membership base fell following a change in refund programmes from credit card providers,…
Well on track in 2024
JDC Group | 14/05/2024
JDC Group (JDC) reported strong Q124 results. Revenue growth accelerated to 21.6% from 10% in FY23, driven by its Advisortech division (+22.6%). In terms…